SequelSEC

BIOXYTRAN, INC BIXT

Pharmaceutical Preparations · CIK 0001445815 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$20.31K
Fiscal year ended 2018-06-30
Operating income
-$275
Fiscal year ended 2018-06-30
Free cash flow
Unavailable
Fiscal year ended 2018-06-30

BIOXYTRAN, INC (BIXT) reported revenue of $20.31K and net income of -$275 for the fiscal year ended 2018-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BIOXYTRAN, INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

BIOXYTRAN, INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2018-06-302018-03-312017-12-312017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Revenue$20.31K$13.32K$144.17K$39.47K$7.44K$58.20K$101.14K$55.63K$31.52K-$2.07M
Cost of revenue$8.12K$15.25K$70.67K$19.40K$13.67K$22.47K$38.20K$18.83K$16.81K$27.95K
Gross profit$12.20K-$1.93K$73.49K$20.08K-$6.24K$35.73K$62.94K$36.80K$14.72K-$4.80K
Operating income-$275-$670-$86.41K-$258.47K-$62.64K$137.23K-$212.04K-$143.38K-$453.09K-$112.91K
Net income-$275-$670-$86.41K-$260.42K-$64.59K$135.28K-$213.99K-$163.00K-$455.04K-$114.95K
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$275-$670-$86.41KUnavailableUnavailableUnavailableUnavailableUnavailable-$455.04KUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$124.86K$25.73K$62.74K$278.54K$56.40K-$101.50K$274.98K$180.18K$467.81K$108.10K
General & administrative$275$670$1.31KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BIOXYTRAN, INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2018-06-302018-03-312017-12-312017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailable$3.05K$11.09K$18.77K$22.71K$9.45K$3.48K
Total assets$686.21K$691.70K$110$21.56K$29.23K$51.67K$81.83K$56.57K$50.19K$55.82K
Current assets$12.76K$13.90K$110$5.65K$8.88K$26.96K$52.66K$22.71K$9.45K$3.48K
Total liabilities$150.11K$178.93K$1.42K$415.40K$384.41K$342.27K$342.70K$268.46K$276.45K$251.04K
Current liabilitiesUnavailableUnavailable$1.42K$415.40K$384.41K$342.27K$342.70K$268.46K$276.45K$251.04K
Total equity incl. NCI-$1.98K-$1.31K-$1.31K-$393.83K-$355.18K-$290.60K-$260.87K-$211.88K-$226.26K-$195.22K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$6.59K$6.72K$5.26KUnavailableUnavailable$6.27K$3.64KUnavailableUnavailableUnavailable
Accounts receivable$4.80K$2.04K$22.96KUnavailableUnavailable$9.60K$30.24KUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

BIOXYTRAN, INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2018-06-302018-03-312017-12-312017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Operating cash flow$5-$80$110-$3.40K-$8.04K-$7.68K-$3.94K-$11.74K-$19.03K-$13.17K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$0-$400$22.35KUnavailableUnavailable$0$0$25.00K$25.00KUnavailable
Net change in cash$5-$80$110-$3.05K-$8.04K-$7.68K-$3.94K$13.26K$5.97K-$8.17K
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

BIOXYTRAN, INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2018-06-302018-03-312017-12-312017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin60.0%-14.5%51.0%50.9%-83.9%UnavailableUnavailable66.2%46.7%Unavailable
Operating marginUnavailableUnavailableUnavailable-654.8%-842.3%UnavailableUnavailable-257.7%-1437.2%Unavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratioUnavailableUnavailable0.08x0.01x0.02xUnavailable0.15x0.08x0.03x0.01x
Revenue YoY growth-48.5%79.1%147.7%-29.0%-76.4%Unavailable-8.7%-6.3%-49.6%Unavailable
Net marginUnavailableUnavailableUnavailable-659.8%-868.6%UnavailableUnavailable-293.0%-1443.4%Unavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BIXT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.